| Dr Marissa A Boeck, MD | |
|
400 Parnassus Ave, San Francisco, CA 94143-2202 | |
| (415) 353-2161 | |
| Not Available |
| Full Name | Dr Marissa A Boeck |
|---|---|
| Gender | Female |
| Speciality | General Surgery |
| Experience | 13 Years |
| Location | 400 Parnassus Ave, San Francisco, California |
| Accepts Medicare Assignments | Yes. She accepts the Medicare-approved amount; you will not be billed for any more than the Medicare deductible and coinsurance. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1003108531 | NPI | - | NPPES |
| Taxonomy | Type | License (State) | Status |
|---|---|---|---|
| 208600000X | Surgery | A154281 (California) | Secondary |
| 2086S0102X | Surgery - Surgical Critical Care | A154281 (California) | Primary |
| Facility Name | Location | Facility Type |
|---|---|---|
| Ucsf Medical Center | San francisco, CA | Hospital |
| Zuckerberg San Francisco General Hosp & Trauma Ctr | San francisco, CA | Hospital |
| Group Practice Name | Group PECOS PAC ID | No. of Members |
|---|---|---|
| University Of California Sfgh Medical Group | 5496668410 | 488 |
| Ucsf Dept Of Surgery | 7719886373 | 156 |
News Archive
Inovio Pharmaceuticals, Inc., a leader in the development of therapeutic and preventive vaccines against cancers and infectious diseases, has reported data demonstrating long-term durability of immune responses induced by VGX-3100, its investigational DNA vaccine for treating cervical dysplasia and cancer caused by human papillomavirus.
ChromoCure, Inc. - The Company announced today, based on the recent validation of its cancer detection approach and efficacy of its proprietary Chromosomal Scanning Technology, that it has retained Patent & Intellectual Property Attorneys to assess its growing Intellectual Property portfolio and secure necessary filings and Patent protections.
Scientists have confirmed one of the brain areas responsible for rapid updating of information during learning - the sort of information we use to negotiate many changing situations in everyday life.
The Will Rogers Institute's annual prize for outstanding contributions to lung research has been awarded to Dr. Anthony Fauci. The $50,000 award was created to honor individuals for extraordinary work leading to advancements in treatment for lung diseases. He is the fourth recipient of the prestigious prize from the Will Rogers Institute.
Provectus Pharmaceuticals, Inc., a development-stage oncology and dermatology biopharmaceutical company, has initiated a Phase 2c clinical trial of PH-10 for psoriasis. This multicenter, randomized controlled Phase 2c study is expected to enroll up to 90 subjects at four different sites, beginning in late December.
› Verified 9 days ago
| Entity Name | University Of California San Francisco |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1861578973 PECOS PAC ID: 4486567229 Enrollment ID: O20031212000897 |
News Archive
Inovio Pharmaceuticals, Inc., a leader in the development of therapeutic and preventive vaccines against cancers and infectious diseases, has reported data demonstrating long-term durability of immune responses induced by VGX-3100, its investigational DNA vaccine for treating cervical dysplasia and cancer caused by human papillomavirus.
ChromoCure, Inc. - The Company announced today, based on the recent validation of its cancer detection approach and efficacy of its proprietary Chromosomal Scanning Technology, that it has retained Patent & Intellectual Property Attorneys to assess its growing Intellectual Property portfolio and secure necessary filings and Patent protections.
Scientists have confirmed one of the brain areas responsible for rapid updating of information during learning - the sort of information we use to negotiate many changing situations in everyday life.
The Will Rogers Institute's annual prize for outstanding contributions to lung research has been awarded to Dr. Anthony Fauci. The $50,000 award was created to honor individuals for extraordinary work leading to advancements in treatment for lung diseases. He is the fourth recipient of the prestigious prize from the Will Rogers Institute.
Provectus Pharmaceuticals, Inc., a development-stage oncology and dermatology biopharmaceutical company, has initiated a Phase 2c clinical trial of PH-10 for psoriasis. This multicenter, randomized controlled Phase 2c study is expected to enroll up to 90 subjects at four different sites, beginning in late December.
› Verified 9 days ago
| Entity Name | Ucsf Dept Of Surgery |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1477627537 PECOS PAC ID: 7719886373 Enrollment ID: O20040102000839 |
News Archive
Inovio Pharmaceuticals, Inc., a leader in the development of therapeutic and preventive vaccines against cancers and infectious diseases, has reported data demonstrating long-term durability of immune responses induced by VGX-3100, its investigational DNA vaccine for treating cervical dysplasia and cancer caused by human papillomavirus.
ChromoCure, Inc. - The Company announced today, based on the recent validation of its cancer detection approach and efficacy of its proprietary Chromosomal Scanning Technology, that it has retained Patent & Intellectual Property Attorneys to assess its growing Intellectual Property portfolio and secure necessary filings and Patent protections.
Scientists have confirmed one of the brain areas responsible for rapid updating of information during learning - the sort of information we use to negotiate many changing situations in everyday life.
The Will Rogers Institute's annual prize for outstanding contributions to lung research has been awarded to Dr. Anthony Fauci. The $50,000 award was created to honor individuals for extraordinary work leading to advancements in treatment for lung diseases. He is the fourth recipient of the prestigious prize from the Will Rogers Institute.
Provectus Pharmaceuticals, Inc., a development-stage oncology and dermatology biopharmaceutical company, has initiated a Phase 2c clinical trial of PH-10 for psoriasis. This multicenter, randomized controlled Phase 2c study is expected to enroll up to 90 subjects at four different sites, beginning in late December.
› Verified 9 days ago
| Entity Name | Ucsf Medical Group Business Services |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1477624104 PECOS PAC ID: 3779497870 Enrollment ID: O20040622001513 |
News Archive
Inovio Pharmaceuticals, Inc., a leader in the development of therapeutic and preventive vaccines against cancers and infectious diseases, has reported data demonstrating long-term durability of immune responses induced by VGX-3100, its investigational DNA vaccine for treating cervical dysplasia and cancer caused by human papillomavirus.
ChromoCure, Inc. - The Company announced today, based on the recent validation of its cancer detection approach and efficacy of its proprietary Chromosomal Scanning Technology, that it has retained Patent & Intellectual Property Attorneys to assess its growing Intellectual Property portfolio and secure necessary filings and Patent protections.
Scientists have confirmed one of the brain areas responsible for rapid updating of information during learning - the sort of information we use to negotiate many changing situations in everyday life.
The Will Rogers Institute's annual prize for outstanding contributions to lung research has been awarded to Dr. Anthony Fauci. The $50,000 award was created to honor individuals for extraordinary work leading to advancements in treatment for lung diseases. He is the fourth recipient of the prestigious prize from the Will Rogers Institute.
Provectus Pharmaceuticals, Inc., a development-stage oncology and dermatology biopharmaceutical company, has initiated a Phase 2c clinical trial of PH-10 for psoriasis. This multicenter, randomized controlled Phase 2c study is expected to enroll up to 90 subjects at four different sites, beginning in late December.
› Verified 9 days ago
| Entity Name | City & County Of San Francisco |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1982737524 PECOS PAC ID: 1658280748 Enrollment ID: O20050309000770 |
News Archive
Inovio Pharmaceuticals, Inc., a leader in the development of therapeutic and preventive vaccines against cancers and infectious diseases, has reported data demonstrating long-term durability of immune responses induced by VGX-3100, its investigational DNA vaccine for treating cervical dysplasia and cancer caused by human papillomavirus.
ChromoCure, Inc. - The Company announced today, based on the recent validation of its cancer detection approach and efficacy of its proprietary Chromosomal Scanning Technology, that it has retained Patent & Intellectual Property Attorneys to assess its growing Intellectual Property portfolio and secure necessary filings and Patent protections.
Scientists have confirmed one of the brain areas responsible for rapid updating of information during learning - the sort of information we use to negotiate many changing situations in everyday life.
The Will Rogers Institute's annual prize for outstanding contributions to lung research has been awarded to Dr. Anthony Fauci. The $50,000 award was created to honor individuals for extraordinary work leading to advancements in treatment for lung diseases. He is the fourth recipient of the prestigious prize from the Will Rogers Institute.
Provectus Pharmaceuticals, Inc., a development-stage oncology and dermatology biopharmaceutical company, has initiated a Phase 2c clinical trial of PH-10 for psoriasis. This multicenter, randomized controlled Phase 2c study is expected to enroll up to 90 subjects at four different sites, beginning in late December.
› Verified 9 days ago
| Entity Name | University Of California Sfgh Medical Group |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1477528503 PECOS PAC ID: 5496668410 Enrollment ID: O20050328001092 |
News Archive
Inovio Pharmaceuticals, Inc., a leader in the development of therapeutic and preventive vaccines against cancers and infectious diseases, has reported data demonstrating long-term durability of immune responses induced by VGX-3100, its investigational DNA vaccine for treating cervical dysplasia and cancer caused by human papillomavirus.
ChromoCure, Inc. - The Company announced today, based on the recent validation of its cancer detection approach and efficacy of its proprietary Chromosomal Scanning Technology, that it has retained Patent & Intellectual Property Attorneys to assess its growing Intellectual Property portfolio and secure necessary filings and Patent protections.
Scientists have confirmed one of the brain areas responsible for rapid updating of information during learning - the sort of information we use to negotiate many changing situations in everyday life.
The Will Rogers Institute's annual prize for outstanding contributions to lung research has been awarded to Dr. Anthony Fauci. The $50,000 award was created to honor individuals for extraordinary work leading to advancements in treatment for lung diseases. He is the fourth recipient of the prestigious prize from the Will Rogers Institute.
Provectus Pharmaceuticals, Inc., a development-stage oncology and dermatology biopharmaceutical company, has initiated a Phase 2c clinical trial of PH-10 for psoriasis. This multicenter, randomized controlled Phase 2c study is expected to enroll up to 90 subjects at four different sites, beginning in late December.
› Verified 9 days ago
| Mailing Address | Practice Location Address |
|---|---|
| Dr Marissa A Boeck, MD 400 Parnassus Ave, San Francisco, CA 94143-2202 Ph: (415) 353-2161 | Dr Marissa A Boeck, MD 400 Parnassus Ave, San Francisco, CA 94143-2202 Ph: (415) 353-2161 |
News Archive
Inovio Pharmaceuticals, Inc., a leader in the development of therapeutic and preventive vaccines against cancers and infectious diseases, has reported data demonstrating long-term durability of immune responses induced by VGX-3100, its investigational DNA vaccine for treating cervical dysplasia and cancer caused by human papillomavirus.
ChromoCure, Inc. - The Company announced today, based on the recent validation of its cancer detection approach and efficacy of its proprietary Chromosomal Scanning Technology, that it has retained Patent & Intellectual Property Attorneys to assess its growing Intellectual Property portfolio and secure necessary filings and Patent protections.
Scientists have confirmed one of the brain areas responsible for rapid updating of information during learning - the sort of information we use to negotiate many changing situations in everyday life.
The Will Rogers Institute's annual prize for outstanding contributions to lung research has been awarded to Dr. Anthony Fauci. The $50,000 award was created to honor individuals for extraordinary work leading to advancements in treatment for lung diseases. He is the fourth recipient of the prestigious prize from the Will Rogers Institute.
Provectus Pharmaceuticals, Inc., a development-stage oncology and dermatology biopharmaceutical company, has initiated a Phase 2c clinical trial of PH-10 for psoriasis. This multicenter, randomized controlled Phase 2c study is expected to enroll up to 90 subjects at four different sites, beginning in late December.
› Verified 9 days ago
Dr. Allan Marc Conway, MD Surgery Medicare: Accepting Medicare Assignments Practice Location: 400 Parnassus Ave Ste A, San Francisco, CA 94143 Phone: 415-353-2537 Fax: 415-353-2669 | |
Alan Zambeli-ljepovic, Surgery Medicare: Medicare Enrolled Practice Location: 513 Parnassus Ave, San Francisco, CA 94143 Phone: 415-476-1239 | |
Dr. Sang-mo Kang, MD Surgery Medicare: Accepting Medicare Assignments Practice Location: 400 Parnassus Ave, San Francisco, CA 94143 Phone: 415-476-1551 Fax: 415-353-8917 | |
Timothy A Chuter, MD Surgery Medicare: Medicare Enrolled Practice Location: 400 Parnassus Ave, San Francisco, CA 94143 Phone: 415-353-4366 Fax: 415-353-4370 | |
Rebecca Plevin, M.D. Surgery Medicare: Accepting Medicare Assignments Practice Location: 1001 Potrero Ave, Rm 3a37, San Francisco, CA 94110 Phone: 206-543-3680 | |
Dr. Eric Kaoru Nakakura, MD Surgery Medicare: Accepting Medicare Assignments Practice Location: 1600 Divisadero St, San Francisco, CA 94115 Phone: 415-353-9846 Fax: 415-353-9958 |